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Summary
AIMS: We aimed to evaluate the interest of adult inpatients
and selected outpatients in engaging in a large, real-life,
hospital-based, genomic medicine research project and in
receiving clinically actionable incidental findings.
METHODS: Within the framework of the cross-sectional
Institutional Biobank of Lausanne, Switzerland, a total of
25 721 patients of the CHUV University Hospital were sys-
tematically invited to grant researchers access to their bio-
medical data and to donate blood for future analyses, in-
cluding whole-genome sequencing. Multivariable logistic
regression analysis was used to identify personal factors,
including age, gender, religion, ethnicity, citizenship, edu-
cation level and mode of admission, associated with will-
ingness to participate in this genomic research project
and with interest in receiving clinically actionable inciden-
tal findings.
RESULTS: The overall participation rate was 79%
(20 343/25 721). Participation rate declined progressively
with age, averaging 83%, 75%, 67% and 62% in patients
aged <64 years (n = 13 108), ≥64 years (n = 12 613), ≥80
years (n = 4557) and ≥90 years (n = 1050), respective-
ly. Factors associated with participation substantially dif-
fered between age strata. Patients less likely to participate
included women (odds ratio 0.86, [95% confidence inter-
val 0.79–0.95] and 0.78 [0.71–0.85] before and after age
64, respectively), non-Swiss (0.81 [0.74–0.90] and 0.58
[0.52–0.65]) and those admitted through the emergency
ward (0.88 [0.79–0.98] and 0.66 [0.60–0.73]). Religion and
marital status were associated with participation among
patients aged <64 years. A total of 19 018 (93%) partic-
ipants were willing to be re-contacted for incidental find-
ings. A high education level was associated with higher
participation rate, but not with higher willingness to receive
incidental findings within the population who had agreed
to participate.
CONCLUSION: A large proportion of adult patients, even
among the elderly, are willing to actively participate and re-
ceive incidental findings in this systematic hospital-based
precision and genomic medicine research program with
broad consent.
Key words: whole genome sequencing, Lausanne Institu-
tional Biobank, participation in genomic medicine research
project
Introduction
Breakthroughs in genomics, in other technologies designed
to characterise and quantify pools of biological molecules
such as proteomics or metabolomics (collectively referred
to as *omic sciences) and in IT technologies open up un-
precedented opportunities to tailor health maintenance and
the diagnosis and treatment of diseases according to the
particular biological profile of an individual, i.e., person-
alised or precision medicine [1]. A particular aspect of pre-
cision medicine pertains to the use of individual genomic
information to optimise disease prevention and treatment
(genomic medicine). The success of genomic medicine
will largely depend, initially, on the ability to link high-
quality clinical data with genomic data from large num-
ber of individuals. To that end, population-based cohorts
have already been assembled, including the UK Biobank
[2] or the Estonian Biobank [3], or are in the process of be-
ing assembled, such as the Precision Medicine Initiative in
the USA [4, 5]. In parallel, major efforts are being devoted
to linking genomic data with medical data retrieved from
electronic medical records [6]. Returning information on
variants involved in drug metabolism or toxicity (pharma-
cogenetics [7]), or on highly penetrant, clinically action-
able variants discovered incidentally may turn into imme-
diate benefits of genomic medicine. The American Col-
lege of Medical Genetics has made recommendations for
returning information pertaining to such incidental find-
ings [8]. Such variants predispose mostly to potentially
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deadly cardiovascular diseases (including prolonged QT,
cardiomyopathies, vascular abnormalities such as Marfan
syndrome or premature atherosclerosis such as familial hy-
percholesterolaemia) or familial forms of cancer, includ-
ing breast, kidney or endocrine neoplasms. Recent analysis
from more than 50 000 sequenced exomes shows that, in a
largely Caucasian population, approximately 3.5% of indi-
viduals are carriers of such variants and could benefit from
genomic medicine [9]. Finally, for genomic medicine to
fully deliver on its promises will require the demonstration
of the clinical utility of the newly generated knowledge,
through appropriate trials; one opportunity is to re-con-
tact cohort participants and enrol them into genetically en-
riched intervention clinical trials [10] or observation stud-
ies for detailed phenotyping [11]. Hospitals with a cohort
linked to a biobank and a dedicated clinical research centre
represent a unique opportunity to address these needs.
Surveys in various countries indicate a relatively high in-
terest in genetics from the population [12–19] and from
patients suffering from selected diseases [20, 21]. In ad-
dition, patients engaged in genetic research are generally
interested in signing a broad general consent [16] and in
being informed about incidental findings [22–26]. A lim-
ited number of studies point to certain interethnic differ-
ences in engaging with genetic research [27]. However, the
size of most studies is limited, ranging from a dozen to
a few hundred participants, the majority of these studies
are based on questionnaires or surveys, rather than real
engagement into genetic research, and only a minority of
studies relate to hospitalised patients. Accordingly, even
though a hospital represents a privileged place to enrol par-
ticipants in genomic research, to what extent hospitalised
patients actually sign a broad consent including the future
possibility for researchers to access their medical records
and perform whole genome sequencing, and are interested
in being re-contacted for incidental findings, remains poor-
ly documented.
The CHUV University Hospital Institutional Biobank
(BIL) in Lausanne, Switzerland [28] is a highly versatile
hospital-based cross-sectional initiative launched in 2013.
Briefly, adult patients admitted to selected wards at CHUV
are systematically contacted individually and informed
about research and the BIL project. Patients are invited to
sign a broad consent, granting researchers access to their
biological samples (leftover and additional material being
collected if no risks and constraints are generated) and to
their electronic medical records, including the possibili-
ty to address future Institutional Review Board-approved
questions which were not necessarily anticipated at the
time consent is obtained, without the need for re-consent.
By signing this consent, patients agree to donate a 9-ml
blood sample for DNA and plasma isolation, for extensive
analyses, including whole genome sequencing and other
*omic analyses. Patients who agree to participate in this
project are offered the option to be re-contacted in the fu-
ture, if findings requiring clinical intervention were inci-
dentally made during these analyses. The project was ap-
proved by the local Ethics Committee (approval number
144/12), and is fully aligned with the Swiss Human Re-
search Act and its Ordinances, which were enacted on 1
January 2014. A recent analysis of the prevalence of mu-
tations causing familial hypercholesterolaemia among BIL
participants with elevated plasma levels of low density
lipoprotein (LDL)-cholesterol [29] provided a proof of
concept that all the steps ranging from data and sample col-
lection to genetic analyses are in place for future genomic
medicine studies.
In the present study, we examined the participation rate and
the personal factors associated with participation and fu-
ture re-contact for incidental findings among patients who
were contacted during the first 3 years of activity of the
BIL.
Material and methods
Study population
The CHUV is a 1463-bed university hospital that serves as
a primary and secondary care centre for the Lausanne area,
and as tertiary care centre for a population of approximate-
ly 1 million people in western Switzerland. Since January
2013, patients hospitalised in selected wards at CHUV and
outpatients from a limited number of clinics are system-
atically contacted and informed about the BIL project and
the general consent, without any prespecified disease ar-
eas. Patients are interviewed about the project by a dedicat-
ed team of research assistants who have been specifically
trained for this task. These face-to-face interviews are con-
ducted at the bedside or during an outpatient visit. Patients
are admitted through the emergency department, or have a
planned, elective admission. In the latter situation, patients
requiring surgery usually attend a prehospitalisation outpa-
tient visit, during which the project is presented and they
are invited to sign the consent. Patients with elective ad-
mission who do not require such a visit are contacted ei-
ther via a specific mailing (since July 2014) or during the
hospitalisation. Patients admitted through the emergency
department are contacted once their medical situation has
stabilised and after they have been transferred from the
emergency room or intensive care unit into a regular ward.
Patients are given the necessary time to consider and dis-
cuss their participation in the project and have the possibil-
ity to revoke their consent at any time. Between 7 January
2013 and 31 December 2015, 29 174 persons were individ-
ually contacted and informed about the BIL project. After
exclusion of 1072 patients who had pending consent sta-
tus at the time of database freeze, 1873 women from the
maternity ward (who were not considered patients as they
did not have any medical or surgical disease conditions),
and 508 patients for whom the dataset was not complete,
25 721 patients were included in the present analyses.
Data collection
The consent and status of biospecimen collection, as well
as a minimal data set, were registered in a dedicated se-
cured web-based database (Labvantage Biobanking Solu-
tion, Somerset NJ). The minimal data set included the ba-
sic demographics (age, sex, origin, ethnicity, marital status,
religion and, since 2014, education level), the way the pa-
tient had been admitted (through emergency, outpatient or
elective visit) and the department where the project was
presented and the patient hospitalised. Patients had the
possibility to participate in the project by signing the broad
consent and have their genetic data and samples used in
a coded/pseudo-anonymised way. Pseudo-anonymisation
was performed in accordance with HIPAA act. In that way,
investigators cannot have access to patients’ personal data,
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and all sensitive information is removed in order to protect
patients’ identities. It is possible to come back to the pa-
tient if necessary, in the case of research results disclosure
for example, by using a specific key that is held by duly
authorised people within the hospital. Patients who agreed
to participate in the project with their genetic data and sam-
ples coded were further asked if they were interested in be-
ing re-contacted in case clinically actionable findings were
to be discovered in future analyses done on their biological
samples.
Statistical analyses
Data were extracted from the database with Access version
2007 and analysed with Stata 14·0 (Stata Corp., College
Station TX). Categorical variables were expressed as num-
ber of people and percentages. Continuous variables were
expressed as mean ± standard deviation (SD). Multiple lo-
gistic regression analyses were used to explore individual
characteristics associated with participation in the BIL and,
among participants, with interest in being re-contacted for
incidental findings. We originally run analyses on 25 721
patients without using education as a covariate and, subse-
quently, on 17 518 patients for whom education level was
available (these data were collected from 2014) and was
used as a covariate. The predicted probability of partici-
pation in the BIL by age and sex (men coded as 0 and
women as 1) was generated from a multiple logistic re-
gression model including admission mode (elective [refer-
ence], outpatient or emergency), citizenship (Swiss coded
as 0 and non-Swiss as 1), marital status (married [ref-
erence], single or other), religion (Catholic [reference],
Protestant or other), and education (low [reference], mid-
dle, high or unknown) for selected analyses, as covariates
coded as dummy variables. We used the “margin” function
in Stata, which generates the predicted probability at spe-
cific age levels (here we arbitrarily chose each decade of
age), separately for men and women, while setting each
confounder to its mean value. Because characteristics as-
sociated with willingness to participate or to receive in-
cidental findings differed by age groups (as assessed by
formal statistical interaction testing), we conducted strati-
fied analyses using 64 years of age as a cut-off, as it was
close to the median age (i.e., 63 years) and happened to
closely match the retirement age in Switzerland (i.e., 65
years). We conducted interaction testing by adding a mul-
tiplication term between the categorical covariate of inter-
est (e.g., religion, nationality, marital status, sex, etc.) and
dichotomised age (coded as 0 below 64 years and 1 oth-
erwise). We then used a likelihood ratio test to assess the
overall statistical significance of the interaction by com-
paring a model with and a model without the interaction
terms.
Results
Study population
The majority of the 25 721 patients invited to participate
in the BIL project during its 3 initial years of recruitment
were men (13 912, 54%), Swiss citizens (18 531, 72%) and
of European descent (21 333, 83%) (table1). Approximate-
ly one third of these patients were reported to be Catholic
(9466, 37%) and one third Protestant (8693, 34%), where-
as the remaining patients (7562, 29%) reported another or
no religion. Age averaged 60.7 ± 19.0 (SD) years, with
4557 patients ≥80 years old and 1050 ≥90 years old (sup-
plementary fig. S1 in appendix 1). More than one third
of participants had been admitted through the emergency
department (9635, 38%), whereas another third consisted
of inpatients admitted for planned, elective admission with
consent mailed and/or presented during the hospitalisation
(8090, 31%). The remaining third (7996, 31%) were pa-
tients to whom the project was presented during an outpa-
tient visit. The distribution according to the ward these pa-
tients were met, as well as their willingness to participate
or receive incidental findings, are presented in supplemen-
tary table S1 (appendix 1). Education level was available
for 17 518 patients, with 3197 (18%), 6180 (35%), 3216
(18%) and 4925 (28%) patients with low (no validated
education or mandatory school certificate), middle (ap-
prenticeship, secondary education, college), high (univer-
sity degree or equivalent) and unknown level, respectively.
Participants’ characteristics across four selected age
groups are presented in table S2.
Participation in the BIL genomic and precision medi-
cine research project
Out of the 25 721 patients included in the analysis, 20 343
(79%) agreed to sign the broad consent form, with the pos-
sibility for researchers to link their clinical data (includ-
ing electronic medical records) with future coded genom-
ic data (table 1). This group constitutes the “participants”
group. A total of 3941 patients refused to participate in the
project, 30 revoked their consent, and 1407 patients agreed
to participate, but with the request that their data and sam-
Figure 1: Predicted probability of participation by sex at spe-
cific age levels. Dots represent the predicted probability of partici-
pation by sex at specific age levels (20 years, 30 years, etc.) gen-
erated from a multiple logistic regression model in which the
outcome was participation (code is 1 for a participant and 0 for a
non-participant) and which included consent place, citizenship, re-
ligion and marital status as covariates. The whiskers represent
95% confidence intervals. The age-specific estimated probabilities
of participation are depicted in blue for men and in red for women.
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ples be anonymised, thus precluding future genetic asso-
ciation studies. Because ability to link medical data to ge-
nomic data, and to re-contact participants is critical for the
type of genomic medicine studies envisioned here, these
latter three groups were merged into the “nonparticipants”
group (5378, 21%).
Whereas the probability of participation was very similar,
across age groups up to 60 years of age, it declined in the
older age groups, both in men and in women (fig. 1). Will-
ingness to participate averaged 83% among the 13 108 pa-
tients aged <64 years, 75% among those aged >64 years
(n = 12 613), 67% in patients aged ≥80 years (n = 4557)
and 62% in patients aged ≥90 years (n = 1050). The pro-
portion of patients who agreed to participate in the project
was slightly lower among the 11 809 women than among
the 13 912 men (77% vs 81%, p <0.001) (table 1).
Personal factors associated with willingness to participate
differed between age strata, with significant interactions (p
values <0.05) of age strata with sex, religion, citizenship,
marital status and admission mode, taken one at a time
(fig. 2). Among patients aged <64 years, women (odds ra-
tio [OR] 0.86, 95% confidence interval [CI] 0.79–0.95), in-
dividuals reporting a religion other than Catholic or Protes-
tant (OR 0.67, 95% CI 0.6–-0.74) as well as non-Swiss
citizens (OR 0.81, 95% CI 0.74–0.90) were less likely to
participate, whereas those with a civil status other than
married or single (OR 1.21, 95% CI 1.06–1.37) were more
likely to participate. The personal factor most strongly as-
sociated with participation was admission mode: people
with emergency admission were less likely to participate
(OR 0.88, 95% CI 0.79–0.98) and those contacted during
an outpatient visit (OR 1.82, 95% CI 1.61–2.05) were more
likely to participate than those with elective hospitalisa-
tion contacted within the hospital setting or via specific
mailing (inpatients). Among patients aged 64 years or old-
er, women (OR 0.78, 95% CI 0.71–0.85), non-Swiss cit-
izen (OR 0.58, 95% CI 0.52–0.65) and those with emer-
gency admission (OR 0.66, 95% CI 0.60–0.73) were less
willing to participate. As was observed in the younger age
strata, the factor most strongly associated with participa-
tion was admission mode. Sensitivity analyses conduct-
ed in the subset of 17 518 patients with information on
education level led to results similar to those for the en-
tire dataset (supplementary fig. S2 in appendix 1). We ob-
served a greater willingness to participate among people
of middle educational level (age <64 years: OR 1.49, 95%
CI 1.26–1.76; age ≥64 years: OR 1.64, 95% CI 1.39–1.93
among) or high education level (age <64 years: OR 1.42,
95% CI 1.17–1.71; age ≥64 years: OR 2.17, 95% CI
1.77–2.66) as compared with those of a low or unknown
education level.
Interest in being re-contacted for incidental findings
Out of 20 343 participants to the BIL project, 19 018
(93%) individuals were willing to be re-contacted for inci-
dental findings (table 1). We observed significant interac-
tions (p-values <0·05) of age strata with admission mode,
sex, marital status and religion, taken one at a time (fig.
3). In both groups of participants (aged <64 years or >64
years), older age and admission through the emergency
ward was associated with less interest in receiving this in-
formation, whereas, admission through the outpatient clin-
ic was associated with a higher interest. Religion other than
Catholic or Protestant was associated with less interest in
the younger age group, whereas among the older age group
being single was associated with less interest. Sensitivity
analyses on the subset of patients with available informa-
tion on education level led to similar results (supplemen-
tary fig. S3 in appendix 1). In contrast to willingness to
participate, education level was not a strong predictor of
interest in receiving incidental findings.
Discussion
Described here is, to the best of our knowledge, the largest
analysis performed to evaluate the factors associated with
Table 1: Patient characteristics, overall and by gender.
All Men Women
Number 25 721 13 912 11 809
Age (in years), mean (SD of mean) 60.7 (19) 60.4 (18) 61.1 (20)
Swiss 18 531 (72) 9759 (70) 8772 (74)Citizenship, n (%)
Non-Swiss 7190 (28) 4153 (30) 3037 (26)
European 21 333 (83) 11 768 (85) 9565 (81)
Other 1422 (5) 727 (5) 695 (6)
Origin, n (%)
Unknown 2966 (12) 1417 (10) 1549 (13)
Married 12 909 (50) 7798 (56) 5111 (43)
Single 5463 (21) 3161 (23) 2302 (19)
Civil status, n (%)
Other* 7349 (29) 2953 (21) 4396 (37)
Catholic 9466 (37) 5049 (36) 4417 (37)
Protestant 8693 (34) 4609 (33) 4084 (35)
Religion, n (%)
Other 7562 (29) 4254 (31) 3308 (28)
Elective 8090 (31) 4667 (34) 3423 (29)
Emergency 9635 (38) 5073 (36) 4562 (39)
Admission mode, n (%)
Outpatients 7996 (31) 4172 (30) 3824 (32)
Yes 20 343 (79) 11 241 (81) 9102 (77)Participation in BIL
No 5378 (21) 2671 (19) 2707 (23)
Among participants
Yes 19 018 (93) 10 535 (94) 8483 (93)Interest in incidental findings, n (%)
No 1325 (7) 706 (6) 619 (7)
BIL = Lausanne Institutional Biobank; SD = standard deviation * Other civil status means divorced, widowed, separated or other types of partnership. Percentages may not add
up vertically to 100% owing to rounding effects.
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participation in a real-life genomic research projects
among hospitalised patients. We found a high participation
rate in this particular systematic hospital-based genomic
medicine research project, with a very large proportion of
these participants interested in being re-contacted for po-
tential clinically actionable incidental findings. Although
willingness to participate declined from 60 years of age on-
wards, it still remained remarkably high even among the
1050 patients aged 90 years and over. Willingness to par-
ticipate was associated with different patient characteris-
tics depending on age.
The overall participation rate (79%) was higher than that
reported in various population surveys [12–19]. A similar-
ly high participation rate was observed across wards with
very different source populations, such as orthopaedics,
plastic surgery, cardiology and oncology. Several factors
may account for this high participation rate. Building trust
and educating the general population about research are
Figure 2: Factors associated with willingness to participate among 25 721 patients. Dots represent odds ratios and bars 95% confidence
intervals from a multivariable logistic model including willingness to participate as the dependent variable, run separately in the two age strata.
The age cut off at 64 years was chosen as it is close to the median age and happens to closely match the retirement age in Switzerland. Pa-
tients aged <64 years are depicted in Panel A, and those aged 64 or older are shown in Panel B.
Figure 3: Factors associated with willingness to receive incidental findings among the 20 343 participants. Dots represent odds ratios
and bars 95% confidence intervals from a multivariable logistic model including willingness to receive incidental findings, among patients hav-
ing accepted to participate, as the dependent variable, run separately in the two age strata.
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important to encourage participation in research projects.
In the present BIL project, each patient was contacted in-
dividually in a face-to-face interview with a research as-
sistant dedicated to this task and specifically trained to in-
form patients, respond to their questions and collect their
consent. The BIL project has also been highly visible, with
broad media coverage and strong interest from the popula-
tion.
A notable strength of this project was the inclusion of a
sizeable number of patients aged ≥80 years (n = 4557) or
≥90 years (n = 1050). Older adults are the fastest growing
part of the population in high and middle income countries,
and the very old represent an increasing proportion of pa-
tients needing care, yet data are scarce in the medical liter-
ature. In Switzerland, life expectancy is high both at birth
(80.8 years for men and 84.9 years for women in 2015,
www.bfs.admin.ch) and at 80 years of age (8.5 years for
men and 10.1 years for women). One may question the in-
terest of using genomic medicine in very old people, but
these people are frequently prescribed multiple drugs and
usually have reduced renal function. Clear applications can
be envisioned, such as maximising drug response and min-
imising adverse drug reactions on the basis of genomic
background [7, 30], even though clinical utility for most of
such applications has not yet been fully established.
Unsurprisingly, the willingness to provide a broad consent
for research and the interest in receiving incidental find-
ings was lower in people older than 80 years than in
younger age group. The reduced participation rate in the
elderly may be due to a limited interest in taking part in
research, a higher prevalence of cognitive decline, a larg-
er proportion of patients with multi-morbidity and hence
more stressful and precarious living conditions [31].
A concern was that the participation rate in the BIL was in-
flated by the situation of the patients, who are hospitalised
and thus in a position of weakness and dependence. The
fact that patients with planned admission who were recruit-
ed either via specific mailing or during their pre-hospital-
isation visit had a similarly high participation rate is reas-
suring. Patients who received specific mailing prior to their
admission were found to be better informed and ready for a
deeper discussion on research when they met the recruiters.
In this particular programme, the vast majority of patients
wanted to be informed about incidental findings that might
require clinical intervention. This observation is aligned
with prior reviews, surveys, qualitative studies, and with
findings from other hospital-based biobanks [22, 23, 26]. It
emphasises the importance of keeping track of the partic-
ipants and of putting in place an infrastructure to support
disclosure, which adds substantial burden, including finan-
cial costs, on investigators and biobank curators [32]. Al-
though a clear distinction needs to be made between in-
cidental findings occurring during routine medical care
and those made in a clinical research setting [33], there
is growing consensus that researchers should be prepared
to return incidental findings to participants who have ex-
pressed such an interest [34, 35]. Whether and how to dis-
close genomic results is a matter of intense discussion, as
genomic results affect not only research participants, but
also their biological relatives, and may induce discrimina-
tion and have other important societal implications.
The observations made here were based on a relatively
large, yet limited number of adult patients recruited within
a single Swiss academic hospital setting. Although extrap-
olation to other populations or other hospitals needs to
be cautious, this study shows a strong engagement for re-
search from adult patients, and illustrates that hospitals
represent an efficient opportunity for recruiting in- and
out-patients from a large panel of wards and disease areas
as participants in genomic medicine initiatives and big data
research.
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Appendix 1
Supplementary tables and figures
Table S1: Distribution of the 25 721 patients, according to the ward
where they were contacted.
All Willingness
to participate
Willingness to
receive inciden-
tal findings†
n %* % %
Visceral surgery 3355 13 83 94
Internal medicine 2858 11 66 89
Cardiology 2701 10 81 93
Traumatology 2506 10 77 92
Other wards 2195 9 82 94
ENT 2020 8 79 95
Orthopaedics 1983 8 86 94
Neurosurgery 1463 6 80 94
Neurology 1304 5 72 94
Urology 1238 5 82 93
Plastic surgery 1090 4 82 95
Vascular surgery 924 4 80 93
Thoracic surgery 877 3 82 94
Cardiovascular
surgery
672 3 75 92
Medical oncology 535 2 82 95
Wards with at least 500 patients are listed separately and the rest in
the “Other wards” category. * Column percentage †Among those who
agreed to participate Percentages may not add up to 100% owing to
rounding effects.
Figure S1: Age distribution of the study population by gender.
The distribution of the 25 721 patients (13 912 males and 11 809
females) included in the analysis according to age is depicted as
kernel density.
Table S2: Patients characteristics across selected age groups.
Age groups
(years)
<64 ≥64 & <80 ≥80 & <90 ≥90
Number 13108 8056 3507 1050
Age (in years), mean (SD
of mean)
45.4 (13.6) 71.4 (4.4) 84.0 (2.8) 92.8 (2.7)
Sex, n (%) women 5979 (45.6) 3392 (42.1) 1781 (50.8) 657 (62.6)
Swiss 8110 (62) 6511 (81) 2971 (85) 939 (89)Citizenship, n (%)
Non-Swiss 4998 (38) 1545 (19) 536 (15) 111 (11)
European 10246 (78) 6912 (86) 3173 (90) 1002 (95)
Other 1224 (9) 161 (2) 31 (1) 6 (1)
Origin, n (%)
Unknown 1638 (13) 983 (12) 303 (9) 42 (4)
Married 6057 (46) 4802 (60) 1,751 (50) 299 (28)
Single 4515 (34) 646 (8) 243 (7) 59 (6)
Civil status, n (%)
Other* 2536 (19) 2608 (32) 1,513 (43) 692 (66)
Catholic 5000 (38) 3007 (34) 1187 (34) 272 (26)
Protestant 3099 (24) 3342 (48) 1680 (48) 572 (54)
Religion, n (%)
Other 5009 (38) 1707 (18) 640 (18) 206 (20)
Elective 4197 (32) 2734 (34) 977 (28) 182 (17)
Emergency 4407 (34) 2693 (33) 1786 (51) 749 (71)
Admission mode, n (%)
Outpatients 4504 (34) 2629 (33) 744 (21) 119 (11)
Yes 10843 (83) 6443 (80) 2410 (69) 647 (62)Participation in BIL
No 2265 (17) 1613 (20) 1097 (31) 403 (38)
Among participants
Yes 10393 (96) 5948 (92) 2153 (89) 524 (81)Interest in incidental find-
ings, n (%) No 450 (4) 495 (8) 257 (11) 123 (19)
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Figure S2: Factors associated with willingness to participate, among patients with information available on education level. This
analysis is restricted to the 17 518 patients for whom information on education level is available (this information was collected from 2014).
Dots represent odds ratios and bars 95% confidence intervals from a multivariable logistic model including willingness to participate as the de-
pendent variable, run separately in the two age strata.
Figure S3: Factors associated with interest in being re-contacted for incidental findings among patients with information available
on education level. This analysis is restricted to the 17 518 patients for whom information on education level is available. Dots represent
odds ratios and bars 95% confidence intervals from a multivariable logistic model including willingness to receive incidental findings, among
patients having accepted to participate, as the dependent variable, run separately in the two age strata.
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